martes, 6 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 21, 2026

Forget Rate Cuts: What if the Fed Needs to Hike Rates in 2026?

View original at finance.yahoo.com
Forget Rate Cuts: What if the Fed Needs to Hike Rates in 2026? The Iran conflict has thrown both the U.S. economic outlook and Fed policy plans out the window…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Small-cap earnings growth expectations are starting to improve

    60% confidence
  • Belief in rate cuts was largely based on the notion that GDP growth was likely to slow and the labor market showed stagnant job growth

    60% confidence
  • Several Fed members expressing hesitation to cut rates in light of inflation remaining stubbornly above target

    60% confidence
  • Fed Funds futures market has been pricing in rate cuts in 2026, with expectations for two rate cuts during the year

    60% confidence
  • Tariffs are paid by the U.S. importer and those higher costs often get passed on to the end consumer, making tariffs inherently inflationary

    60% confidence
  • Rate cuts are meant to support an economy that's deteriorating. If corporate earnings are already strong and in some cases accelerating, that indicates the economy really isn't in that bad of shape

    60% confidence
  • United States government insists it won't withdraw from conflict until Iran surrenders

    60% confidence
  • If the current oil spike was due to a supply driven event, it may only be temporarily inflationary, and long-term macro fundamentals should outweigh short-term shocks

    60% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com